- Home
- MESO vs LILAK Comparison
MESO vs LILAK Comparison
Compare MESO & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- LILAK
- Stock Information
- Founded
- MESO 2004
- LILAK 2017
- Country
- MESO Australia
- LILAK Bermuda
- Employees
- MESO N/A
- LILAK N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- LILAK Cable & Other Pay Television Services
- Sector
- MESO Health Care
- LILAK Telecommunications
- Exchange
- MESO Nasdaq
- LILAK Nasdaq
- Market Cap
- MESO 1.3B
- LILAK 1.1B
- IPO Year
- MESO N/A
- LILAK N/A
- Fundamental
- Price
- MESO $11.06
- LILAK $6.34
- Analyst Decision
- MESO Buy
- LILAK Buy
- Analyst Count
- MESO 4
- LILAK 3
- Target Price
- MESO $18.00
- LILAK $10.27
- AVG Volume (30 Days)
- MESO 205.5K
- LILAK 1.2M
- Earning Date
- MESO 08-28-2025
- LILAK 08-05-2025
- Dividend Yield
- MESO N/A
- LILAK N/A
- EPS Growth
- MESO N/A
- LILAK N/A
- EPS
- MESO N/A
- LILAK N/A
- Revenue
- MESO $5,670,000.00
- LILAK $4,441,000,000.00
- Revenue This Year
- MESO $178.09
- LILAK $2.45
- Revenue Next Year
- MESO $305.06
- LILAK $3.11
- P/E Ratio
- MESO N/A
- LILAK N/A
- Revenue Growth
- MESO N/A
- LILAK N/A
- 52 Week Low
- MESO $5.78
- LILAK $4.23
- 52 Week High
- MESO $22.00
- LILAK $10.93
- Technical
- Relative Strength Index (RSI)
- MESO 50.02
- LILAK 61.36
- Support Level
- MESO $10.32
- LILAK $5.92
- Resistance Level
- MESO $10.86
- LILAK $6.65
- Average True Range (ATR)
- MESO 0.35
- LILAK 0.31
- MACD
- MESO 0.00
- LILAK 0.01
- Stochastic Oscillator
- MESO 45.04
- LILAK 68.37
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.